Circassia has a highly experienced management team with a proven track record in product development and marketing. After successful two fundraising rounds the company by a consortium of world-class venture capital and institutional investors, secured including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual is complete.

ToleroMune technology has additional potential regulatory and supply benefits for Circassia. The state-of – the-art manufacturing fits changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and the elimination of batch-to – batch potency variability that of many of many currrent treatments.Products in USA osmotica is PHARMA partners with a PANACEA BIOTEC sell a generic items to U.S.[ Tenderness Information ].